Effectiveness of saffron in the treatment of mild to moderate Alzheimer’s disease with ADAS-cog score
Keywords:
clinical trial, cholinesterase inhibitor, saffron, dementiaAbstract
Introduction: large levels of glucocorticoids and stress results structural and functional changes in brain and hippocampus, limbic system has a key role in cognitive functions including learning and memory. Alzheimer’s disease (AD) is a chronic neurodegenerative disease. Objective: the AIM of this study was to assess the efficacy of saffron in the treatment of mild to moderate Alzheimer’s disease (AD). Methods: fifty-six patients of 55 years old were eligible to participate in this study. the study is a double-blind study of parallel groups of patients with AD. Results: saffron is effective similar to donepezil in the treatment of mild to moderate AD after 22 weeks. The safety of saffron is comparatively similar like donepezil. The side effects presented with saffron and donepezil groups likely same. The major parameter taken was Alzheimer’s disease assessment Scale-cognitive subscale score evaluated with baseline. The safety of saffron was also recorded systemically. Participators were given a capsule saffron 30 mg/day (15 mg twice daily) or donepezil 10 mg/day (5 mg twice per day). Conclusion: this study provides mainly suggests that possible therapeutic effect of saffron extract at least in short-term treatment of patients with mild-to0moderate Alzheimer’s disease.
Downloads
References
Abdullaev FI, Espinosa-Aguirre JJ (2004) Biomedical properties of saffron and its potential use in cancer therapy and chemoprevention trials. Cancer Detect Prev 28:426–432 DOI: https://doi.org/10.1016/j.cdp.2004.09.002
Abe K, Saito H (2000) Effects of saffron extract and its constituent crocin on learning behaviour and long-term potentiation. Phyt-other Res 14:149–152 DOI: https://doi.org/10.1002/(SICI)1099-1573(200005)14:3<149::AID-PTR665>3.0.CO;2-5
Abe K, Sugiura M, Shoyama Y, Saito H (1998) Crocin antagonizes ethanol inhibition of NMDA receptor-mediated responses in rat hippocampal neurons. Brain Res 787:132–138 DOI: https://doi.org/10.1016/S0006-8993(97)01505-9
Akhondzadeh S (1999) Hippocampal synaptic plasticity and cognition. J Clin Pharm Ther 24:241–248 DOI: https://doi.org/10.1046/j.1365-2710.1999.00231.x
Akhondzadeh S (2007) Herbal medicine in the treatment of psychiatric and neurological Disorders. In: L’Abate L (ed) Low cost approaches to promote physical and mental health: theory research and practice. Springer, New York, pp 119–138 DOI: https://doi.org/10.1007/0-387-36899-X_6
AkhondzadehBasti A, Moshiri E, Noorbala AA, Jamshidi AH, Abbasi SH, Akhondzadeh S (2007) Comparison of petal of Crocus sativus L. and fluoxetine in the treatment of depressed outpatients: a pilot double-blind randomized trial. ProgNeuropsychopharmacolBiol Psychiatry 31:439–442 DOI: https://doi.org/10.1016/j.pnpbp.2006.11.010
Akhondzadeh S, Abbasi SH (2006) Herbal medicine in the treatment of Alzheimer's disease. Am J Alzheimers Dis Other Demen21:113–118 DOI: https://doi.org/10.1177/153331750602100211
Akhondzadeh S, Noroozian M, Mohammadi M, Ohadinia S, JamshidiAH, Khani M (2003a) Salvia officinalis extract in the treatment of patients with mild to moderate Alzheimer's disease: a doubleblind, randomized and placebo-controlled trial. J Clin Pharm Ther 28:53–59 DOI: https://doi.org/10.1046/j.1365-2710.2003.00463.x
Akhondzadeh S, Noroozian M, Mohammadi M, Ohadinia S, JamshidiAH, Khani M (2003b) Melissa officinalis extract in the treatment of patients with mild to moderate Alzheimer's disease: a double blind, randomised, placebo controlled trial. J NeurolNeurosurgPsychiatry 74:863–866. DOI: https://doi.org/10.1136/jnnp.74.7.863
Akhondzadeh S, Tahmacebi-Pour N, Noorbala AA, Amini H, Fallah-PourH, Jamshidi AH, Khani M (2005) Crocus sativus L. in the treatment of mild to moderate depression: a double-blind, randomized and placebo-controlled trial. Phytother Res 19:148–151. DOI: https://doi.org/10.1002/ptr.1647
Akhondzadeh S, ShafieeSabet M, Harirchian MH, Togha M, Cheraghmakani H, Razeghi S, Hejazi SS, Yousefi MH, AlimardaniR, Jamshidi AH, Zare F, Moradi A (2009) Saffron in the treatment of patients with mild to moderate Alzheimer’s disease: a 16-week, randomized and placebo controlled trial. J Clin Pharm Ther (in press) Becker RE, Greig NH (2008) Alzheimer's disease drug development in 2008 and beyond: problems and opportunities.Curr Alzheimer Res 5:346–357. DOI: https://doi.org/10.1111/j.1365-2710.2009.01133.x
Birks J, Grimley A, Evans J (2009) Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev 21: CD003120. DOI: https://doi.org/10.1002/14651858.CD003120.pub3
Citron M (2004) Strategies for disease modification in Alzheimer’s disease. Nat Rev Neurosci 5:677–685 Ernst E (2006) Herbal medicines—they are popular, but are they also safe? Eur J ClinPharmacol 62:1–2. DOI: https://doi.org/10.1038/nrn1495
Folstein MF, Folstein SE, McHugh PR (1975) Mini-mental state.A practical method or grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189–198. DOI: https://doi.org/10.1016/0022-3956(75)90026-6
Golde TE (2005) The Aβ hypothesis: leading us to rationally designed therapeutic strategies for the treatment or prevention of Alzheimer disease. Brain Pathol 15:84–87 DOI: https://doi.org/10.1111/j.1750-3639.2005.tb00104.x
Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL (1982) A new clinical scale for the staging of dementia. Br J Psychiatry 140:566–572 DOI: https://doi.org/10.1192/bjp.140.6.566
Izzo AA, Capasso F (2006) Herbal medicines to treat Alzheimer’s disease. Trends PharmacolSci 28:47–48 DOI: https://doi.org/10.1016/j.tips.2006.12.001
Mantle D, Pickering AT, Perry E (2002) Medical plant extracts for treatment of dementia. A review of their pharmacology, efficacy and tolerability. CNS Drugs 13:201–213 DOI: https://doi.org/10.2165/00023210-200013030-00006
McKhann G, Drachman D, Folstein M, Katzman R, Price D, StadlanEM (1984) Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 34:939–944 DOI: https://doi.org/10.1212/WNL.34.7.939
Papandreou MA, Kanakis CD, Polissiou MG, Efthimiopoulos S, Cordopatis P, Margarity M, Lamari FN (2006) Inhibitory activity on amyloid-beta aggregation and antioxidant properties of Crocus sativus stigmas extract and its crocin constituents. J Agric Food Chem 15:8762–8768 DOI: https://doi.org/10.1021/jf061932a
Pitsikas N, Zisopoulou S, Tarantilis PA, Kanakis CD, Polissiou MG, Sakellaridis N (2007) Effects of the active constituents of Crocus sativus L. crocins on recognition and spatial rats' memory. BehavBrain Res 183:141–146 DOI: https://doi.org/10.1016/j.bbr.2007.06.001
Rafii MS, Aisen PS (2009) Recent developments in Alzheimer's disease therapeutics. BMC Med 19:7 Rosen WG, Mohs RC, Davis KL (1984) A new rating scale for Alzheimer’s disease. Am J Psychiatry 141:1356–1364 DOI: https://doi.org/10.1186/1741-7015-7-7
Schmidt M, Betti G, Hensel A (2007) Saffron in phytotherapy: pharmacology and clinical uses. Wien Med Wochenschr157:315–319 DOI: https://doi.org/10.1007/s10354-007-0428-4
Starkstein SE, Mizrahi R, Power BD (2008) Depression in Alzheimer's disease: phenomenology, clinical correlates and treatment. Int Rev Psychiatry 20:382–388 DOI: https://doi.org/10.1080/09540260802094480
Sugiura M, Shoyama Y, Saito H, Nishiyama N (1995a) Crocinimproves the ethanol-induced impairment of learning behaviors of mice in passive avoidance tasks. Proc Japan AcadSer B 1:319–324 DOI: https://doi.org/10.2183/pjab.71.319
Sugiura M, Shoyama Y, Saito H, Abe K (1995b) Ethanol extract of Crocus sativus L. antagonizes the inhibitory action of ethanol on hippocampal long-term potentiation in vivo. Phytother Res 9:100–104 DOI: https://doi.org/10.1002/ptr.2650090204
Tedeschi G, Cirillo M, TessitoreA, Cirillo S (2008) Alzheimer's disease and other dementing conditions. NeurolSci 29 (Suppl):301–307 DOI: https://doi.org/10.1007/s10072-008-1003-5
Tsuno N (2009) Donepezil in the treatment of patients with Alzheimer's disease. Expert Rev Neurother 9:591–598 DOI: https://doi.org/10.1586/ern.09.23
Wake G, Court J, Pickering A, Lewis R, Wilkins R, Perry E (2000) CNS acetylcholine receptor activity in European medicinal plants traditionally used to improve failing memory. J Ethnopharmacol69:105–114 DOI: https://doi.org/10.1016/S0378-8741(99)00113-0
Published
How to Cite
Issue
Section
Copyright (c) 2024 International journal of health sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles published in the International Journal of Health Sciences (IJHS) are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJHS right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.
Articles published in IJHS can be copied, communicated and shared in their published form for non-commercial purposes provided full attribution is given to the author and the journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
This copyright notice applies to articles published in IJHS volumes 4 onwards. Please read about the copyright notices for previous volumes under Journal History.
